XML 34 R22.htm IDEA: XBRL DOCUMENT

Long-Term Investment (Tables)

12 Months Ended

Dec. 31, 2018

Longterm Investment Tables Abstract

Schedule of ownership percentages of investee

		Ownership percentage
		December 31,				December 31,				Accounting
Name of related party		2018				2017				treatment
Rgene Corporation			23.90	%			N/A			Equity Method

Schedule of long-term investment

		December 31,				December 31,
		2018				2017
Equity Method Investments, net of impairment
Rgene Corporation		$	-				N/A
Total		$	-				N/A

Schedule of balance sheets

														Pro Forma						Pro Forma
		ABVC				BioKey				BioLite				Adjustment				Note		Combined
ASSETS
Current Assets
Cash and cash equivalents		$	40,044			$	636,666			$	186,644				-					$	863,354
Restricted cash and cash equivalents			16,093				-				-				-						16,093
Accounts receivable, net			-				43,204				-				-						43,204
Accounts receivable - related parties, net			-				147,848				-				-						147,848
Other receivable			-				-				39,005				-						39,005
Due from related parties			40,000				-				79,287				(59,810	)		{f}			59,477
Inventory			-				-				1,318				-						1,318
Prepaid expense and other current assets			136				-				223,759				-						223,895
Total Current Assets			96,273				827,718				530,013				(59,810	)					1,394,194

Property and equipment, net			-				58,150				510,066										568,216
Goodwill, net			-				-				-				43,531,445			{e}			43,531,445
Long-term investments			-				-				3,488,169										3,448,169
Deferred tax assets			-				-				1,347,995										1,347,995
Security Deposits			-				10,440				27,418										37,858
Total Assets		$	96,273			$	896,308			$	5,903,661			$	43,471,635					$	50,367,877

LIABILITIES AND EQUITY
Current Liabilities
Short-term bank loan			-				-				899,250				-						899,250
Long-term bank loan - current portion			-				-				39,835				-						39,835
Notes payable			-				-				510,447				-						510,447
Accrued expenses and other current liabilities			555,449				83,026				687,709				-						1,326,184
Due to related parties			4,462,775				-				3,341,005				(58,684	)		{f}			7,745,096
Convertible notes payable			300,000				-				-										300,000
Convertible notes payable - related parties			250,000				-				-										250,000
Total Current Liabilities			5,568,224				83,026				5,478,246				(58,684	)					11,070,812

Long-term bank loan			-				-				15,257				-						15,257
Tenant security deposit			-				2,880				-				-						2,880
Convertible notes payable			-				-				-				-						-
Convertible notes payable - related parties			250,000				-				-				-						250,000
Accrued interest			27,467				-				-				-						27,467

Total Liabilities			5,845,691				85,906				5,493,503				(58,684	)					11,366,416

Equity
Preferred stock			-				18,633,097				-				(18,633,097	)		{c}			-
Common stock			213,927				774,293				4,121				(4,121	)		{a}			318,486
															74,998			{a}
															(771,793	)		{b}
															7,428			{b}
															22,133			{c}
Additional paid-in capital			13,914,556				82,265				10,862,995				(70,877	)		{a}			59,018,959
															(82,265	)		{e}
															44,312,285			{e}
															(10,000,000	)		{g}
Stock subscription receivable			-				(1,667	)			-				1,667			{e}			-
Accumulated deficit			(19,877,901	)			(18,677,586	)			(11,445,109	)			18,677,586			{e}			(12,209,446	)
															6,817,848			{g}
															2,295,716			{h}
															10,000,000			{g}
Other comprehensive income			-				-				670,541				(14,689	)		{g,h}			655,852
Treasury stock			-				-				-				(6,750,000	)		{g}			(9,100,000	)
															(2,350,000	)		{h}
Total Stockholders’ deficit			(5,749,418	)			810,402				92,548				43,530,319						38,683,851
Noncontrolling interest			-				-				317,610				-						317,610
Total Equity			(5,749,418	)			810,402				410,158				43,530,319						39,001,461

Total Liabilities and Equity		$	96,273			$	896,308			$	5,903,661			$	43,471,635						50,367,877

Schedule of statements of operation

														Pro Forma								Pro Forma
		ABVC				BioKey				BioLite				Adjustment				Note				Combined

Revenues		$	-			$	510,197			$	6,956											$	517,153

Cost of revenues			-				4,809				185,280												190,089

Gross profit			-				505,388				(178,324	)											327,064

Operating expenses
Selling, general and administrative expenses			695,148				669,322				893,570												2,258,040
Research and development expenses			669,668				430,917				319,053												1,419,638
Stock based compensation			28,800				-				-												28,800
Total operating expenses			1,393,616				1,100,239				1,212,623												3,706,478

Loss from operations			(1,393,616	)			(594,851	)			(1,390,947	)											(3,379,414	)

Other income (expense)
Interest income			93				4,598				5,119												9,810
Interest expense			(155,930	)			-				(306,821	)											(462,751	)
Rental income			-				-				11,924												11,924
Impairment loss			-				-				(63,663	)											(63,663	)
Investment loss			(549	)			-				(395,476	)											(396,025	)
Gain/Loss on foreign exchange changes			-				-				7,307												7,307
Gain/Loss on investment in equity securities			(2,549,451	)			-				(192,463	)											(2,741,914	)
Other income (expense)			-				630				(5,154	)											(4,524	)
Total other income (expenses)			(2,705,837	)			5,228				(939,227	)											(3,639,836	)

Loss before provision for income tax			(4,099,453	)			(589,623	)			(2,330,174	)											(7,019,250	)

Provision for income tax (benefit)			1,850				800				(366,947	)											(364,297	)

Net loss			(4,101,303	)			(590,423	)			(1,963,227	)											(6,654,953	)

Net loss attributable to noncontrolling interests			-				-				489,151												489,151

Net loss attributable to ABVC and subsidiaries			(4,101,303	)			(590,423	)			(1,474,067	)											(7,144,104	)
Foreign currency translation adjustment			-				-				86,786												86,786
Comprehensive Income (Loss)		$	(4,101,303	)		$	(590,423	)		$	(1,560,862	)										$	(7,230,890	)

Net loss per share attributable to common stockholders
Basic and diluted		$	(0.02	)																		$	(0.03	)
Weighted average number of common shares outstanding
Basic and diluted			213,884,105																				214,156,988

Schedule of equity investments

		For the Years Ended December 31,
		2018				2017
Share of equity method investee losses		$	(549	)			N/A
Impairments			(2,549,451	)			N/A
Total losses on equity investments		$	(2,550,000	)			N/A